Dendritic cell-based immunotherapy for cancer and relevant challenges for transfusion medicine

Transfusion Medicine Reviews

Volumn 18, Issue 3, 2004, Pages 189-202

  Voss, Ching Y ^a   Albertini, Mark R ^b   Malter, James S ^a,c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; RECOMBINANT INTERLEUKIN 2; TUMOR ANTIGEN; TUMOR VACCINE;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; B CELL LYMPHOMA; BLOOD BANK; BLOOD TRANSFUSION; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL FUNCTION; CELL ISOLATION; CELL MATURATION; CELLULAR IMMUNITY; CLINICAL TRIAL; DENDRITIC CELL; DNA MODIFICATION; DRUG TARGETING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSURVEILLANCE; KIDNEY CARCINOMA; LIVER CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MOLECULAR BIOLOGY; MYELOID LEUKEMIA; NASOPHARYNX CANCER; NEUROBLASTOMA; OVARY CANCER; PANCREAS CANCER; PROTEIN TARGETING; REVIEW; SIDE EFFECT; T CELL LYMPHOMA; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT INDICATION; TUMOR IMMUNOLOGY;

EID: 3242726950     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmrv.2004.03.005     Document Type: Article

References (111)

1. Bates W.D., Gray D.W., Dada M.A., et al. Lymphoproliferative disorders in Oxford renal transplant recipients. J Clin Pathology. 56:2003;439-446
2. Drobyski W.R., Qazi R. Spontaneous regression in non-Hodgkin's lymphoma Clinical and pathogenetic considerations. Am J Hematol. 31:1989;138-141
3. Yu Z., Restifo N.P. Cancer vaccines progress reveals new complexities. J Clin Invest. 110:2002;289-294
4. Chopra R., Goldstone A.H., Pearce R., et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma A case-controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol. 10:1992;1690-1695
5. Kolb H.J., Schattenberg A., Goldman J.M., et al. European group for blood and marrow transplantation working party chronic leukemia. Graft-verses- leukemia effect of donor lymphocyte transfusion in marrow grafted patients. Blood. 86:1995;2041-2050
6. Collins R. Jr, Shpilberg O., Drobyski W.R., et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 15:1997;433-444
7. Dunn G.P., Bruce A.T., Ikeda H., et al. Cancer immunoediting from immunosurveillance to tumor escape. Nat Immunol. 3:2002;991-998
8. Khong H.T., Restifo N.P. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol. 3:2002;999-1005
9. Hahne M., Rimoldi D., Schroter M., et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand Implication for tumor immune escape. Science. 274:1996;1302-1304
10. Gabrilovich D.I., Chen H.L., Girgis K.R., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 2:1996;1096-1103
11. Unger M.A., Rishi M., Clemmer V.B., et al. Characterization of adjacent breast tumors using oligonucleotide microarrays. Breast Cancer Res. 3:2001;336-341
12. Theobald M., Ruppert T., Kuckelkorn U., et al. The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J Exp Med. 1188:1998;1017-1028
13. Musiani P., Modesti A., Giovarelli M., et al. Cytokine, tumor-cell death and immunogenicity A question of choice. Immunol Today. 18:1997;32-36
14. Walker P.R., Saas P., Dietrich P.Y. Role of Fas ligand (CD95 L) in immune escape the tumor cell strickes back. J Immunol. 158:1997;4521-4524
15. Chopin D., Barei-Moniri R., Maille P., et al. Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression. Am J Pathol. 162:2003;1139-1149
16. Morgan D.J., Kreuwel H.T., Fleck S., et al. Activation of low-avidity CTL specific for a self-epitope results in tumor rejection but not autoimmunity. J Immunol. 160:1998;643-651
17. Mantovani S., Garbelli S., Palermo B., et al. Molecular and functional bases of self-antigen recognition in long-term persistent melanocyte-specific CD8+ T cells in one vitiligo patient. J Invest Dermatol. 121:2003;308-314
18. Gabrilovich D.I., Corak J., Ciernik I.F., et al. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res. 3:1997;483-490
19. Gabrilovich D.I., Ishida T., Nadof S., et al. Antibodies to vascular endotheial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res. 5:1999;2963-2970
20. Bell D., Chomarat P., Broyles D., et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med. 190:1999;1417-1426
21. Coventry B.J. CD1a positive putative tumor infiltrating dendritic cells in human breast cancer. Anticancer Res. 19:1999;3183-3187
22. Troy A.J., Summers K.L., Davidson P.J.T., et al. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin Cancer Res. 4:1998;585-593
23. Troy A.J., Davidson P., Atkinson C., et al. Phenotypic characterization of the dendritic cell infiltrate in prostate cancer. J Urol. 160:1998;214-219
24. Troy A.J., Davidson P.J.T., Atkinson C.H., et al. CD1a dendritic cells predominate in transitional cell carcinoma of bladder and kidney but are minimally activated. J Urol. 161:1999;1962-1967
25. Schreiner T.U., Lischka G., Schaumburg-Lever G. Langerhans' cells in skin tumors. Arch Dermatol. 131:1995;187-190
26. Garcia-Plata D., Lessana-Leibowitch M., Palangie A., et al. Immunophenotype analysis of dendritic cells and lymphocytes associated with cutaneous malignant melanomas. Invasion Metastasis. 15:1995;125-134
27. Toriyama K., Wen D.R., Paul E., et al. Variations in the distribution, frequency, and phenotype of Langerhans cells during the evolution of malignant melanoma of the skin. J Invest Dermatol. 100:1993;269s-273s
28. Kiertscher S.M., Luo J., Dubinett S.M., et al. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol. 164:2000;1269-1276
29. Remmel E., Terracciano L., Noppen C., et al. Modulation of dendritic cell phenotype and mobility by tumor cells in vitro. Human Immunol. 62:2001;39-49
30. Hart D.N.J. Dendritic cells and their emerging clinical applications. Pathology. 33:2001;479-492
31. Robinson S., Patterson S., English N., et al. Human peripheral blood contains two distinct lineages of dendritic cells. Eur J Immunol. 29:1999;2769-2778
32. Cella M., Jarrossay D., Facchietti F., et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med. 8:1999;919-929
33. Ito T., Amakawa R., Inaba M., et al. Differential regulation of human blood dendritic cell subsets by IFNs. J Immunol. 166:2001;2961-2969
34. Ho C.S.K., Munster D., Pyke C.M., et al. Spontaneous generation and survival of blood dendritic cells in mononuclear cell culture without exogenous cytokines. Blood. 99:2002;2897-2904
35. Fearnley D.B., Whyte L.F., Carnoutsos S.A., et al. Monitoring human blood dendritic cell numbers in normal individuals and in stem cell transplantation. Blood. 93:1999;728-736
36. Wong E.C., Maher V.E., Hines K., et al. Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy. Cytotherapy. 3:2001;19-29
37. Rouard H., Leon A., Reys S.D., et al. A closed and single-use system for monocyte enrichment Potential for dendritic cell generation for clinical applications. Transfusion. 43:2003;481-487
38. Dhodapkar M.V., Steinnman R.M., Krasovsky J., et al. Antigen-specific inhabition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med. 193:2001;233-238
39. Nestle F.O., Banchereau J., Hart D. Dendritic cells on the move from bench to bedside. Nat Med. 7:2001;761-765
40. Pullarkat V., Lau R., Lee S.M., et al. Large-scale monocyte enrichment coupled with a closed culture system for the generation of human dendritic cells. J Immunol Methods. 267:2002;173-183
41. Bell D., Young J.W., Banchereau J. Dendritic cells. Adv Immunol. 72:1999;255-324
42. Timmerman J.M., Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med. 50:1999;507-529
43. Mahnke K., Guo M., Lee S., et al. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J Cell Biol. 151:2000;673-684
44. Clark G.J., Angel N., Kato M., et al. The role of dendritic cells in the innate immune system. Microbes Infect. 2:2000;257-272
45. Lanzavecchia A., Sallusto F. Regulation of T cell immunity by dendritic cells. Cell. 106:2001;263-266
46. Ferrari G., Knight A.M., Watts C., et al. Distinct intracellular compartment involved invariant chain degradation and peptide loading of major histocompatibility complex (MHC) class II molecules. J Cell Biol. 139:1997;1433-1446
47. McLellan A.D., Starling G.C., Williams L.A., et al. Activation of human peripheral blood dendritic cells induces the CD86 costimulatory molecule. Eur J Immunol. 25:1995;2064-2068
48. Starling G.C., McLellan A.D., Egner W., et al. Intercellular adhesion molecule-3 is a costimulatory ligand for LFA-1 expressed on human blood dendritic cells. Eur J Immunol. 25:1995;2528-2532
49. Adema G.J., Hartgers F., Verstraten R., et al. A dendrtic cell derived C-C chemokine that preferentially attracts naive T cells. Nature. 387:1997;713-715
50. Sorg R.V., McLellan A.D., Hock B.D., et al. Human dendritic cells express functional interleukin-7. Immunobiology. 198:1998;26-38
51. Rissoan M., Soumelis V., Kadowaki N., et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science. 283:1999;1183-1186
52. Humrich J., Jenne L. Viral vectors for dendritic cell-based immunotherapy. Curr Top Microbiol Immunol. 276:2003;241-259
53. Tuettenberg A., Jonuleit H., Tuting T., et al. Priming of T cells with Ad-transduced DC followed by expansion with peptide-pulsed DC significantly enhances the induction of tumor-specific CD8+ T cells Implications for an efficient vaccination strategy. Gene Ther. 10:2003;243-250
54. Mahvi D.M., Burkholder J.K., Turner J., et al. Particle-mediated gene transfer of granulocyte-macrophage colony-stimulating factor cDNA to tumor cells Implication for a clinically relevant tumor vaccine. Hum Gene Ther. 7:1996;1535-1543
55. Mahvi D.M., Shi F.S., Yang N.S., et al. Immunization by particle-mediated transfer of the granulocyte-macrophage colony-stimulating factor gene into autologous tumor cells in melanoma or sarcoma patients Report of a phase I/IB study. Hum Gene Ther. 13:2002;1711-1721
56. Loskog A., Totterman T.H., Bohle A., et al. In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154. Cancer Gene Ther. 9:2002;846-853
57. Satoh Y., Esche C., Gambotto A., et al. Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice. J Exp Ther Oncol. 2:2002;337-349
58. Sharma S., Yang S.C., Batra R.K., et al. Intratumoral therapy with cytoking gene-modified dendritic cells in murine lung cancer models. Methods Mol Med. 75:2003;711-722
59. Tsuji H., Kawaguchi S., Wada T., et al. Adenovirus-mediated in vivo B7-1 gene transfer induces anti-tumor immunity against pre-established primary tumor and pulmonary metastasis of rat osteosarcoma. Cancer Gene Ther. 9:2002;747-755
60. McCarthy D.O., Glowacki N., Schell K., et al. Antigenicity of huan melanoma cells transfected to express the B7-1 co-stimulatory molecule (CD80) varies with the level of B7-1 expression. Cancer Immunol Immunother. 49:2000;85-93
61. Renkist N., Castellic C., Robbins P.F., et al. A list of human tumor antigens recognized by T cells. Cancer Immunol Immunother. 50:2001;3-15
62. Scanlan M.J., Gure A.O., Jungbluth A.A., et al. Cancer/testis antigens an expanding family of targets for cancer immunotherapy. Immunol Rev. 188:2002;22-32
63. Gjertsen G.C., Bjorheim J., Saeterdal I., et al. Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12 Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumor cells carrying this mutation. Int J Cancer. 72:1997;784-790
64. Linard B., Bezieau S., Benlalam H., et al. A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion. J Immunol. 168:2002;4802-4808
65. Eynde B.V.D., Peeters O., Backer O.D., et al. A new family of genes coding for an antigen recognized by autologus cytolytic T lymphocytes on a human melanoma. J Exp Med. 182:1995;689-698
66. Dudley M.E., Wunderlich J.R., Robbins P.F., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 298:2002;850-854
67. Magarian-Blander J., Ciborowski P., Hsia S., et al. Intercellular and intracellular events following the MHC-restricted TCR recognition of a tumor-specific peptide epitope on the epithelial antigen MUC1. J Immunol. 160:1998;3111-3117
68. Xia J., Tanaka Y., Koido S., et al. Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells. J Immunol. 170:2003;1980-1986
69. Galea-Lauri J., Darling D., Mufti G., et al. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens Evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol Immunother. 51:2002;299-310
70. Soruri A., Fayyazi A., Neumann C., et al. Ex vivo generation of human anti-melanoma autologous cytolytic T cells by dendritic cell/melanoma cell hybridomas. Cancer Immunol Immunother. 50:2002;307-314
71. Kotera Y., Shimizu K., Mule J. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res. 61:2001;8105-8109
72. Lambert L., Gibson G.R., Maloney M., et al. Equipotent generation of protective antitumor immunity by various methods of dendritic cell loading with whole cell tumor antigens. J Immunother. 24:2001;232-236
73. Toes R.E., van der Voort E.I., Schoengerger S.P., et al. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J Immunol. 160:1998;4449-4456
74. den Boer T.H., Diehl L., van Mierlo G.J.D., et al. Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance. J Immunol. 167:2001;2522-2528
75. Parmiani G., Castelli C., Dalerba P., et al. Cancer immunotherapy with peptide-based vaccines What have we achieved? Where are we going? J Natl Cancer Inst. 94:2002;805-818
76. Fong L., Hou Y., Rivas A., et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A. 98:2001;8809-8814
77. Briand J.P., Benkirane N., Guichard G., et al. A retro-inverso peptide corresponding to the GH loop of foot-and-mouth disease virus elicits high levels of long-lasting protective neutralizing antibodies. Proc Natl Acad Sci U S A. 94:1997;12545-12550
78. Zhou Y., Bosch M.L., Salgaller M.L. Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity. J Immunother. 25:2002;289-303
79. Peterson A.C., Harlin H., Gajewski T.F. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol. 21:2003;2342-2348
80. O'Rourke M.G., Johnson M., Lanagan C., et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother. 52:2003;387-395
81. Marten A., Flieger D., Renoth S., et al. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells Preclinical results and outcome of first clinical phase I/II trial. Cancer Immunol Immunother. 51:2002;637-644
82. Iwashita Y., Tahara K., Goto S., et al. A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunol Immunother. 52:2003;155-161
83. Pecher G., Haring A., Kaiser L., et al. Mucin gene (MUC1) transfected dendritic cells as vaccine Results of a phase I/II clinical trial. Cancer Immunol Immunother. 51:2002;669-673
84. Pinilla J., Cathcart K., Korontsvit T., et al. A phase II trial of patients with CML using a multivalent BCR-ABL oncogen product fusion peptide vaccine. Proc Am Soc Clin Oncol. 22:2002;168. (abstr)
85. Su Z., Dannull J., Heiser A., et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 63:2003;2127-2133
86. Lin C.L., Lo W.F., LEE T.H., et al. Immunization with Epstein-Barr virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res. 62:2002;6952-6958
87. Timmerman J.M., Czerwinski D.K., Davis T.A., et al. Idiotype-pulsed dendritic cell vaccine for B-cell lymphoma Clinical and immune responses in 35 patients. Blood. 99:2002;1517-1526
88. Stift A., Friedl J., Dubsky P., et al. Dendritic cell-based vaccination in solid cancer. J Clin Oncol. 21:2003;135-142
89. Geiger J.D., Hutchinson R.J., Hohenkirk L.F., et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 61:2001;8513-8519
90. Disis M.L., Rinn K., Knutson K.L., et al. Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. Blood. 99:2002;2845-2850
91. Maier T., Tun-Kyi A., Tassis A., et al. Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood. 102:2003;2338-2344
92. Meidenbauer N., Marienhagen J., Laumer M., et al. Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J Immunol. 170:2003;2161-2169
93. Whiteside T.L., Zhao Y., Tsukishiro T., et al. Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell response to a dendritic cell-based multipeptide vaccine in patients with melanoma. Clin Cancer Res. 9:2003;641-649
94. Keilholz U., Weber J., Finke J.H., et al. Immunologic monitoring of cancer vaccine therapy Results of a workshop sponsored by the society for biological therapy. J Immunother. 25:2002;97-138
95. Chang A.E., Li Q., Jiang G., et al. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J Clin Oncol. 21:2003;884-890
96. Couzin J. Select T cells, given space, shrink tumors. Science. 297:2002;1973-1975
97. Motta M.R., Castellani S., Rizzi S., et al. Generation of dendritic cells from CD14+ monocytes positively selected by immunomagnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti-idiotype vaccination. Br J Hematol. 121:2003;240-250
98. Cao H., Verge V., Baron C., et al. In vitro generation of dendritic cells from human blood monocytes in experimental conditions compatible for in vivo cell therapy. J Hematother Stem Cell Res. 9:2000;183-194
99. Kalinski P., Schuitemaker J., Hikens C., et al. Final maturation of dendritic cells is associated with impaired responsiveness in IFN-r and to bacterial IL-12 inducer Ability of mature dendritic cells to produce IL-12 during the interaction with Th cells. J Immunol. 162:1999;3231-3236
100. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature. 392:1998;245-252
101. Celluzzi C.M., Welbon C. A simple cryopreservation method for dendritic cells and cells used in their derivation and functional assessment. Transfusion. 43:2003;488-494
102. Voss C.Y., Selvaggi S.M., Warner T.F., et al. Autologous T lymphocytes stimulated by tumor antigen-loaded dendritic cells revealed anti-melanoma activity in conjugation assay. Am J Clin Pathol. 120:1993;469. (abstr)
103. Ratta M., Curti A., Fogli M., et al. Efficient presentation of tumor idiotype to autologous T-cells by CD83+dendritc cells derived from highly purified circulating CD14+ monocytes in multiple myeloma patients. Exp Hematol. 28:2000;931-940
104. Campoli M., Chang C.C., Ferrone S. HLA class I antigen loss, tumor immune escape and immune selection. Vaccine. 20:(suppl):2002;A40-A45
105. Marincola F.M., Jaffee E.M., Hicklin D.J., et al. Escape of human solid tumors from T cell recognition Molecular mechanisms and functional significance. Adv Immunol. 74:2000;181-273
106. Seliger B., Maeurer M.J., Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today. 21:2000;455-464
107. Seliger B., Abken H., Ferrone S. HLA-G and MIC expression in tumors and their role in anti-tumor immunity. Trends Immunol. 24:2003;82-87
108. Salgaller M.L. A manifesto on the current state of dendritic cells in adoptive immunotherapy. Transfusion. 43:2003;422-424
109. Itoh T., Ueda Y., Kawashima I., et al. Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen. Cancer Immunol Immunother. 51:2002;99-106
110. Nunes E. Cellular therapy standards. 2003;. AABB News July/August:41-43
111. Kielpinski G. Hospital-based manufacturing of cellula therapy products. 2003;. AABB News July/August:38-40